CN110022936A - 用γ-酮醛清除剂预防和治疗心房颤动/扑动 - Google Patents

用γ-酮醛清除剂预防和治疗心房颤动/扑动 Download PDF

Info

Publication number
CN110022936A
CN110022936A CN201780054986.2A CN201780054986A CN110022936A CN 110022936 A CN110022936 A CN 110022936A CN 201780054986 A CN201780054986 A CN 201780054986A CN 110022936 A CN110022936 A CN 110022936A
Authority
CN
China
Prior art keywords
compound
member ring
optionally
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780054986.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·T·默里
L·J·罗伯茨二世
V·阿玛尔纳特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN110022936A publication Critical patent/CN110022936A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201780054986.2A 2016-07-07 2017-07-07 用γ-酮醛清除剂预防和治疗心房颤动/扑动 Pending CN110022936A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359705P 2016-07-07 2016-07-07
US62/359,705 2016-07-07
PCT/US2017/041211 WO2018009875A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Publications (1)

Publication Number Publication Date
CN110022936A true CN110022936A (zh) 2019-07-16

Family

ID=60913210

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780054986.2A Pending CN110022936A (zh) 2016-07-07 2017-07-07 用γ-酮醛清除剂预防和治疗心房颤动/扑动

Country Status (11)

Country Link
US (2) US20190247375A1 (https=)
EP (1) EP3481505B1 (https=)
JP (1) JP7179353B2 (https=)
CN (1) CN110022936A (https=)
AU (1) AU2017293950B2 (https=)
BR (1) BR112019000251A2 (https=)
CA (1) CA3030149A1 (https=)
ES (1) ES3040735T3 (https=)
MX (1) MX393913B (https=)
PL (1) PL3481505T3 (https=)
WO (1) WO2018009875A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249562A1 (en) * 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249562A1 (en) * 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIDOROVA等: "Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells", 《JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY》 *

Also Published As

Publication number Publication date
EP3481505B1 (en) 2025-09-03
PL3481505T3 (pl) 2026-01-26
MX2019000120A (es) 2019-04-01
BR112019000251A2 (pt) 2019-04-16
AU2017293950B2 (en) 2023-06-15
JP2019520389A (ja) 2019-07-18
WO2018009875A1 (en) 2018-01-11
AU2017293950A1 (en) 2019-01-31
CA3030149A1 (en) 2018-01-11
MX393913B (es) 2025-03-24
EP3481505A1 (en) 2019-05-15
JP7179353B2 (ja) 2022-11-29
US20240189291A1 (en) 2024-06-13
EP3481505C0 (en) 2025-09-03
US20190247375A1 (en) 2019-08-15
ES3040735T3 (en) 2025-11-04
EP3481505A4 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
Wang et al. The mitophagy pathway and its implications in human diseases
Joshi et al. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease
Errico et al. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia
Joshi et al. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis
Allen et al. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy
Chow et al. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis
Athauda et al. The ongoing pursuit of neuroprotective therapies in Parkinson disease
Zeng et al. Neurotrophins enhance CaMKII activity and rescue amyloid-β-induced deficits in hippocampal synaptic plasticity
Ferguson et al. Non-sirtuin histone deacetylases in the control of cardiac aging
Aharony et al. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits
Michelucci et al. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia
Kelliny et al. A new approach to model sporadic Alzheimer’s disease by intracerebroventricular streptozotocin injection in APP/PS1 mice
JP7542662B2 (ja) 加齢性疾患及び／又は変性疾患に使用される医薬配合剤
Ranek et al. Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner
JP2014529628A (ja) 皮膚色素沈着を調節するための方法
Lopez et al. Increased constitutive nitric oxide production by whole body periodic acceleration ameliorates alterations in cardiomyocytes associated with utrophin/dystrophin deficiency
Lopez et al. Enhancing endogenous nitric oxide by whole body periodic acceleration elicits neuroprotective effects in dystrophic neurons
Lim et al. Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301L-BiFC mice
Palomo et al. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy
Kim et al. Neuroprotective effects of N-adamantyl-4-methylthiazol-2-amine against amyloid β-induced oxidative stress in mouse hippocampus
US20240189291A1 (en) Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers
Zhang et al. Crotoxin potentiates L-type calcium currents and modulates the action potential of neonatal rat cardiomyocytes
Sakuma et al. Molecular mechanisms controlling skeletal muscle mass
Lee et al. Astrocytic MAOB-GABA axis as a molecular brake on repair following spinal cord injury
Sikazwe et al. Alzheimer’s drug discovery maze: a snap view of the past decade’s diverse pharmacological targets for the disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination